ReviewBiomarker insights2018
Nkx2-3-A Slippery Slope From Development Through Inflammation Toward Hematopoietic Malignancies.
Review in Biomarker insights, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Assessment of apoptosis and autophagy in oral squamous cell carcinoma cell line treated with salivary exosomes.Odontology · 2026Article
- Integrating single-cell RNA sequencing and spatial transcriptomics reveals the therapeutic effect of nitazoxanide in head and neck squamous cell carcinoma.Discover oncology · 2025Article
- Gastric cancer genomics study using reference human pangenomes.Life science alliance · 2025Article
- Article
- Shared Genetic Characteristics of Coronary Artery Disease and Peripheral artery Disease: Insights From Integrated Bioinformatics Analysis of RNA-Sequencing Data.Bioinformatics and biology insights · 2025Article
- Nkx2.3 transcription factor is a key regulator of mucous cell identity in salivary glands.Developmental biology · 2024Article
- Quantitative Analysis of NKX2-3 Expression in Human Colon: An Immunohistochemical Study.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2024Article
- Article
- Postnatal expansion of mesenteric lymph node stromal cells towards reticular and CD34Nature communications · 2022Article
- Article
- Article
- Development and Validation of an Autophagy-Related Signature for Head and Neck Squamous Cell Carcinoma.BioMed research international · 2021Article
- Ameliorated Autoimmune Arthritis and Impaired B Cell Receptor-Mediated CaInternational journal of molecular sciences · 2020Article
- Deregulated NKL Homeobox Genes in B-Cell Lymphoma.Cancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of peripheral lymphoid tissues from the mesoderm is the result of a complex convergence combining lymphohematopoietic differentiation with the local specification of nonhematopoietic mesenchymal components. Although the various transcriptional regulators with fate-determining effects in diversifying the mobile leukocyte subsets have been thoroughly studied and identified, the tissue-specific determinants promoting the regional differentiation of resident mesenchyme are less understood. Of these factors, various members of the NK-class Nkx paralogues have emerged as key regulators for the organogenesis of spleen and mucosal lymphoid tissues, and recent data have also indicated their involvement in various pathological events, including gut inflammation and hematopoietic malignancies. Here, we summarize available data on the roles of Nkx2-3 in lymphoid tissue development and discuss its possible value as a developmental marker and disease-associated pathogenic trait.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.